72 results on '"Vancheri C."'
Search Results
2. Comorbidity Clusters in IPF: Unraveling the Impact of Pulmonary Hypertension in the European ILD Registry (eurIPFreg) Cohort
3. Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey
4. EPH200 Healthcare Resource Consumption of Patients with Chronic Obstructive Pulmonary Disease Treated with Triple and Dual Therapy and Experiencing an Acute Exacerbation
5. 17:10-17:20 LMWH-induced miRNA changes in peripheral blood mononuclear cells in pregnancies with unexplained recurrent pregnancy loss
6. Low molecular weight heparin -induced miRNA changes in peripheral blood mononuclear cells in pregnancies with unexplained recurrent pregnancy loss
7. Effects of nintedanib in patients with idiopathic pulmonary fibrosis and varying severities of cough*
8. Effets du nintédanib chez des patients atteints de fibrose pulmonaire idiopathique et présentant des sévérités variables de toux
9. Effects of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Varying Severities of Cough
10. AB0528 CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL
11. The DIAMORFOSIS (Diagnosis and Management of Lung Cancer and Fibrosis) Survey
12. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
13. Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Subgroup Analyses by TORVAN Stage
14. Analyse intermédiaire des patients atteints de pneumopathie interstitielle diffuse (PID) - Étude STARLINER
15. Differences in the Approach to Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE IPF) Between Expert Centres and General Pulmonologists: Results from an International Survey
16. Analysis of Effectiveness of Pirfenidone in Subgroups of Idiopathic Pulmonary Fibrosis Based on Real World Data from European IPF Registry
17. Possible Value of Antifibrotic Drugs in Patients with Progressive Fibrosing Non-IPF Interstitial Lung Diseases
18. Lung CT densitometry in IPF for the prediction of disease severity and mortality
19. Ein globaler Blick auf akute Exazerbationen der idiopathischen Lungenfibrose (AE-IPF): Ergebnisse einer internationalen Umfrage
20. PRS1 - REAL-WORLD EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE: FINDINGS FROM AN OBSERVATIONAL CHART REVIEW OF A LARGE COHORT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENTS IN ITALY
21. Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY
22. Amélioration de la capacité vitale forcée (CVF) avec le nintédanib chez des patients atteints de fibrose pulmonaire idiopathique (FPI) : résultats des essais INPULSIS
23. Nanofat 2.0: Experimental Evidence for a Fat Grafting Rich in Mesenchymal Stem Cells
24. Effect of Pirfenidone on cough in patients with Idiopathic Pulmonary Fibrosis
25. P161 Unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF) – insights from patient chart review in five european countries
26. What We Know About the Pathogenesis of Idiopathic Pulmonary Fibrosis
27. Symptome respiratorischer Infekte gehen oftmals der Diagnose einer idiopathische pulmonalen Fibrose (IPF) voraus
28. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
29. In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbitux®) in a model of human non-small cell lung cancer expressing EGFR and HER2
30. Validation du questionnaire de santé K-BILD au cours des pneumopathies interstitielles diffuses
31. Regulation of macroautophagy in amiodarone induced pulmonary fibrosis
32. Slowing progression of idiopathic pulmonary fibrosis with pirfenidone: from clinical trials to real-life experience
33. Regulation of macroautophagy in amiodarone induced pulmonary fibrosis
34. P200 A qualitative european survey of patients perceptions of current management of idiopathic pulmonary fibrosis
35. Common pathways in idiopathic pulmonary fibrosis and cancer
36. 1068 CIRCULATING FIBROCYTES AS A POTENTIAL NON INVASIVE MARKER OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
37. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
38. Protective Effect of Resveratrol on TGF-β-Induced Lung Fibroblast Differentiation.
39. Exhaled Breath Condensate (EBC) Cysteinyl Leukotrienes (cys-LTs) in Gastroesophageal Reflux Disease-Related Asthma.
40. Interleukin‐6 receptor superantagonist Sant7 inhibits TGF‐β‐induced proliferation of human lung fibroblasts
41. TGF-β1 targets the GSK-3β/β-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts
42. A case of pulmonary langerhans cell histiocytosis in a young woman with coeliac disease
43. Enhancing effect of dipyridamole inhalation on adenosine-induced bronchospasm in asthmatic patients
44. CCR5 and CCR3 expression on T CD3+ lymphocytes from HIV/Leishmania co-infected subjects
45. Activation of cytosolic phospholipase A2 and 15-lipoxygenase by oxidized low-density lipoproteins in cultured human lung fibroblasts
46. Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to β-amyloid
47. Intranasal steroid reduces exhaled bronchial cysteinyl leukotrienes in allergic patients
48. Cellular and molecular effects of protons: Apoptosis induction and potential implications for cancer therapy
49. Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor
50. Nasal fluticasone reduces exhaled bronchial cysteinyl leukotrienes in allergic patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.